Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for #Parkinson’s Disease “The successful completion of the SAD/MAD in 72 healthy subjects with no serious adverse events or discontinuations related to adverse events and the ability to achieve therapeutic plasma levels with oral dosing further confirm our belief in GT-02287’s potential to be a transformative therapy for Parkinson’s disease patients,” commented Gain’s Executive Chairman, Khalid Islam, Ph.D. “We remain on track with our recent guidance and look forward to continuing to advance GT-02287 through clinical development and initiating a trial in Parkinson’s disease patients by Q4 2024.” https://lnkd.in/eyFziRv7
My best congratulations to Gain and especially to Raffaella Pozzi and the development team for those results!
Congratulations to everybody involved in this fantastic achievement, especially to Raffaella Pozzi for the great job done in such short time!
Congratulations to entire team involved in discovery and development of GT-02287🎉. This is significant gain towards patient safety and improvement of life suffering from chronic illness of PD.
Important development towards bringing GBA1 targeting therapies to Parkinson's disease patients!
Congrats to the whole Team on this great achievement!
Amazing news!
Congratulations to the Gain team on successful completion of MAD of phase 1
Great Job 👏 Raffaella Pozzi 🔝
Partner at NYTCP (Former Google, Microsoft and Entrepreneur)
1moCongratulations to Gain Therapeutics on successfully completing the MAD phase of the Phase 1 study for GT-02287. This milestone brings new hope for #Parkinson's disease treatment